Share the Video:

Panel discussion and Q&A with addiction researchers

Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks

Substance use disorder has become a public health emergency, with the number of afflicted adults across the country jumping from twenty million in 2019 to forty million in the first year of the pandemic. Drug overdose deaths reached over 100,000 nationwide in 2020. Meanwhile, current treatment options apply counseling and behavioral therapies which have high rates of recidivism. Drawing on a long history of research, recent studies are investigating psychedelic-assisted therapy for a variety of new applications in substance use disorders. Join us to consider the role that this potential paradigm for addiction treatment may play and what it will take to confirm its efficacy.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Psychedelics, addiction, and recovery

Psychedelic-assisted therapy's history, Bill W's admiration, and the need for peer support group understanding are discussed in relation to sobriety, recovery, and psychedelics.

Kevin Franciotti, Reilly Capps, Celeste Alvarez, Danielle Nova, Rick Barnett, Juliana Mulligan

PS2023 Harm Reduction Policy and Advocacy Public Benefit Research and Science Social Justice

First responder and law enforcement perspectives on decriminalization and crisis response

First responders and law enforcement discuss challenges and opportunities on the crisis frontlines, exploring substance decriminalization effects, harm reduction, and public health-focused approaches for more compassionate crisis response models.

Lt Diane Goldstein (Ret), Chief Joseph Montoya (DPD), Sarko Gergarian, Kate Gonella

PS2023 Harm Reduction Health Equity Policy and Advocacy Psychedelic Assisted Therapy Research and Science Therapy Ethics

Telemedicine models for supporting psychedelic therapy

Panel explores how telemedicine can enhance psychedelic therapy practice, discussing benefits and risks of virtual care in light of pandemic-induced regulatory changes and improved meeting tech.

Juan Pablo Cappello, Jonathan Sabbagh

PS2023 Business Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science

The evolving financial landscape for psychedelic medicine

Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.

Henry Elkus

PS2023 Health Equity Policy and Advocacy Psychedelic Assisted Therapy Public Benefit Research and Science

Achieving market access and reimbursement for psychedelic therapy

Panel experts discuss insurance coverage requirements for wide accessibility of psychedelic therapy, addressing what payors will need to support the treatments.

Elliot Marseille, Dan Grossman, Sherry Rais, Leslie Nylund

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research Research and Science

What Will People Think? Revealing Public Knowledge, Belief, and Perceptions of Psychedelics

Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll

Imran Khan

PS2023 Harm Reduction Policy and Advocacy Psilocybin Psychedelic Assisted Therapy Research Substance Use Disorder

Psilocybin Treatment of Tobacco Addiction: From a Wing and a Prayer to Federally Funded Psychedelic Therapy Research

Psilocybin research journey: investigating its use for treating tobacco addiction. Includes pilot study, comparative efficacy study, and upcoming multi-site clinical trial funded by NIDA.

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science Social Justice

Intellectual property: shadows and solutions

Traditional cultures use psychedelics, but companies are patenting therapies and compounds based on them. Discussion explores IP system improvements for innovation and public health protection.

Chris Byrnes, Laurel Kilgour, Leslie Booher

PS2023 Business Harm Reduction Policy and Advocacy Public Benefit Research and Science Social Justice

Growing up: The next cycle of venture funding for psychedelic companies

Commercial investment dominates psychedelic sector funding, primarily for drug discovery. Non-commercial projects need financial backing for drug policy reform, public health education, harm reduction, and diversity initiatives. Strategic funding can

Daniel Goldberg, Andrew Chomer, Lindsay Hoover, Sasha Cohen

Panel discussion and Q&A with addiction researchers

Become a MAPS Member with a monthly donation

Related Videos